Tumours from patients 10 and 14 harboured the highest TMB (Figure 3, Supplementary Figure S3), but they were clustered in the IT-resistant group and showed short stable disease and progressive disease as the best response to anti-PD-1/PD-L1, respectively (Figure 1). Here, CD274 is linked to neoplasm.